Marbofloxacin is a fluoroquinolone antimicrobial agent developed exclusively for veterinary use. Marbofloxacin exhibits high bactericidal activity against a broad spectrum of aerobic Gram-negative and some Gram-positive bacteria, as well as Mycoplasma spp. As the third generation fluoroquinolone, Marbofloxacin also mainly targets replication and transcription enzymes such as DNA gyrase and topoisomerase IV, which are both essential for bacterial viability. Marbofloxacin has a mycoplasmacidal effect during the exponential phase but not during the lag phase, in both the M. hyopneumoniae 116 wild-type strain and a clone isolated 4 days post-marbofloxacin treatment in vivo at the therapeutic dose.

 June 21, 2017

prudect name : Marbofloxacin is a fluoroquinolone antimicrobial agent developed exclusively for veterinary use. Marbofloxacin exhibits high bactericidal activity against a broad spectrum of aerobic Gram-negative and some Gram-positive bacteria,…

📌
0💬 read more

prudect name : Medroxyprogesterone 17-acetateSynonyms: CAS NO: 71-58-9Molecular Formula: C24H34O4Molecular Weight: 386.53Purity: 98% minSolubility: Storage:

prudect name : Medroxyprogesterone 17-acetate Synonyms: CAS NO: 71-58-9Molecular Formula: C24H34O4Molecular Weight: 386.53Purity: 98% minSolubility: Storage: −20°C web site: www.medchemexpress.com References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18534229

📌
0💬 read more

MGCD265 is a tyrosine kinase inhibitor that targets the MET, VEGFR-1, VEGFR-2, VEGFR-3, RON and TIE2 receptor tyrosine kinases, which appear to play key roles in tumour development and blood vessel formation (angiogenesis) and tumour survival. MGCD265 is currently in phase I single-agent clinical trials for solid tumour cancers and in phase II trials for solid tumours and NSCLC

prudect name : MGCD265 is a tyrosine kinase inhibitor that targets the MET, VEGFR-1, VEGFR-2, VEGFR-3, RON and TIE2 receptor tyrosine kinases, which appear to play key roles in tumour…

📌
0💬 read more

MPC-3100 has been completed in phase I clinical trials for the treatment of refractory or relapsed cancer.

prudect name : MPC-3100 has been completed in phase I clinical trials for the treatment of refractory or relapsed cancer.MPC-3100 Synonyms: CAS NO: 958025-66-6Molecular Formula: C22H25BrN6O4SMolecular Weight: 549.44Purity: 98% minSolubility:…

📌
0💬 read more

mitomycine C is a methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species. Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and produces interstrand DNA cross-links, thereby inhibiting DNA synthesis. Preferentially toxic to hypoxic cells, mitomycin C also inhibits RNA and protein synthesis at high concentrations.

prudect name : mitomycine C is a methylazirinopyrroloindoledione antineoplastic antibiotic isolated from the bacterium Streptomyces caespitosus and other Streptomyces bacterial species. Bioreduced mitomycin C generates oxygen radicals, alkylates DNA, and…

📌
0💬 read more

MK-5108 inhibits Aurora-A activity in an ATP-competitive manner. MK-5108 shows robust selectivity against the other family kinases Aurora-B (220-fold) and Aurora-C (190-fold) in the biochemical assay. MK-5108 also reveals high selectivity for Aurora-A over other protein kinases. MK-5108 inhibits only one kinase (TrkA) with <100-fold selectivity. MK-5108 may be more Aurora-A selective than MLN8054. Consistent with the induction of pHH3-positive cells, MK-5108 induces accumulation of cells in the G2-M phase. MK-5108 inhibits the proliferation of tumor cells including HCC1143, AU565, MCF-7, HCC1806 and CAL85-1 with an IC50 of 0.42 ¦ÌM, 0.45 ¦ÌM, 0.52 ¦ÌM, 0.56¦ÌM and 0.74 ¦ÌM, respectively.

prudect name : MK-5108 inhibits Aurora-A activity in an ATP-competitive manner. MK-5108 shows robust selectivity against the other family kinases Aurora-B (220-fold) and Aurora-C (190-fold) in the biochemical assay. MK-5108…

📌
0💬 read more

IC50 Value: MLN120B (20 umol/L) induced up to 35% and 75% inhibition, assessed by MTT assay and [3H]thymidine uptakein multiple myeloma cell lines, respectively. NF-¦ÊB pathway blockers, such as MLN120B, are currently being explored for treatment of inflammatory diseases such as COPD and asthma[3]. in vitro: MLN120B inhibits both baseline and tumor necrosis factor-¦Á-induced nuclear factor-¦ÊB activation, associated with down-regulation of I¦ÊB¦Á and p65 nuclear factor-¦ÊB phosphorylation. MLN120B triggers 25% to 90% growth inhibition in a dose-dependent fashion in multiple myeloma cell lines and significantly augments tumor necrosis factor-¦Á-induced cytotoxicity in MM.1S cells. MLN120B augments growth inhibition triggered by doxorubicin and melphalan in both RPMI 8226 and IL-6-dependent INA6 cell lines. Neither IL-6 nor IGF-1 overcomes the growth-inhibitory effect of MLN120B. MLN120B inhibits constitutive IL-6 secretion by BMSCs by 70% to 80% without affecting viability. Importantly, MLN120B almost completely blocks stimulation of MM.1S, U266, and INA6 cell growth, as well as IL-6 secretion from BMSCs, induced by multiple myeloma cell adherence to BMSCs.MLN120B mediates anti-human multiple myeloma cell activity in vivo using a novel SCID-hu model, in which multiple myeloma cells grow in vivoin the context of the human bone marrow microenvironment. Eight SCID mice were implanted with human fetal bone chips (SCID-hu), into which human IL-6-dependent INA6 cells were directly injected. These mice were treated orally with either MLN120B (50 mg/kg) or vehicle control twice daily for 3 weeks[1]. Oral administration of ML120B inhibited paw swelling in a dose-dependent manner (median effective dosage 12 mg/kg twice daily) and offered significant protection against arthritis-induced weight loss as well as cartilage and bone erosion

prudect name : IC50 Value: MLN120B (20 umol/L) induced up to 35% and 75% inhibition, assessed by MTT assay and [3H]thymidine uptakein multiple myeloma cell lines, respectively. NF-¦ÊB pathway blockers,…

📌
0💬 read more

Suvorexant (MK-4305) is a potent, selective, and orally bioavailable antagonist of OX1R and OX2R currently under clinical investigation as a novel therapy for insomnia.Orexins/hypocretins are key neuropeptides responsible for regulating central arousal and reward circuits. Two receptors respond to orexin signaling, orexin 1 receptor (OX1R) and orexin 2 receptor (OX2R) with partially overlapping nervous system distributions. Genetic studies suggest orexin receptor antagonists could be therapeutic for insomnia and other disorders with disruptions of sleep and wake. Suvorexant (MK-4305) was found.

prudect name : Suvorexant (MK-4305) is a potent, selective, and orally bioavailable antagonist of OX1R and OX2R currently under clinical investigation as a novel therapy for insomnia.Orexins/hypocretins are key neuropeptides…

📌
0💬 read more

prudect name : MestranolSynonyms: CAS NO: 72-33-3Molecular Formula: C21H26O2 Molecular Weight: 310.44Purity: 98% minSolubility: Storage:

prudect name : Mestranol Synonyms: CAS NO: 72-33-3Molecular Formula: C21H26O2 Molecular Weight: 310.44Purity: 98% minSolubility: Storage: −20°C web site: www.medchemexpress.com References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18534076

📌
0💬 read more

prudect name : Methyl 2-bromomethyl-3-nitrobenzoateSynonyms: CAS NO: 98475-07-1Molecular Formula: C9H8BrNO4Molecular Weight: 274.07Purity: 98%Solubility: Storage: −20°C

prudect name : Methyl 2-bromomethyl-3-nitrobenzoate Synonyms: CAS NO: 98475-07-1Molecular Formula: C9H8BrNO4Molecular Weight: 274.07Purity: 98%Solubility: Storage: −20°C 2 years web site: www.medchemexpress.com References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18533904

📌
0💬 read more
« Previous
1 … 663 664 665 666 667 … 825
Next »